Define cancer & treatment Classify anti cancer drug

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Now I have comprehensive content from Katzung's Pharmacology. Let me compile the full, well-structured answer.

Cancer: Definition, Treatment & Classification of Anticancer Drugs


1. DEFINITION OF CANCER

Cancer (malignant neoplasm) is a group of diseases characterized by uncontrolled, autonomous proliferation of cells that have escaped the normal regulatory mechanisms governing cell growth and division. These cells acquire the ability to:
  • Grow without normal growth signals (self-sufficiency)
  • Ignore growth-inhibitory signals
  • Evade apoptosis (programmed cell death)
  • Replicate indefinitely (replicative immortality)
  • Stimulate new blood vessel formation (angiogenesis)
  • Invade local tissues and spread to distant sites (metastasis)
Key distinctions:
FeatureBenign TumorMalignant Tumor (Cancer)
Growth rateSlowRapid
InvasionNoYes
MetastasisNoYes
Cell differentiationWell-differentiatedPoorly differentiated
CapsuleUsually presentAbsent
Recurrence after removalRareCommon
Cancer is classified by tissue of origin:
  • Carcinoma - from epithelial cells (e.g., breast, lung, colon cancer)
  • Sarcoma - from connective/mesenchymal tissue (e.g., bone, muscle)
  • Leukemia - from blood-forming cells
  • Lymphoma - from lymphoid tissue
  • Myeloma - from plasma cells

2. TREATMENT OF CANCER

Cancer treatment may be aimed at cure, control, or palliation, and typically involves one or more of the following modalities:

A. Surgery

  • First-line for solid, localized tumors
  • Removes the primary tumor mass
  • Can be curative for early-stage cancers (e.g., resection of colon cancer)

B. Radiation Therapy

  • Uses ionizing radiation to damage DNA of cancer cells
  • Effective for localized tumors
  • Used as definitive therapy, adjuvant, or palliative treatment
  • Can be external beam or brachytherapy (internal)

C. Chemotherapy

  • Systemic drug therapy targeting rapidly dividing cells
  • Most chemotherapeutic drugs inhibit DNA, RNA, or protein synthesis
  • Effects: decreased fibroblast proliferation, inhibited angiogenesis, reduced wound matrix formation
  • Side effects include neutropenia, anemia, thrombocytopenia, and immunosuppression (per Mulholland & Greenfield's Surgery)

D. Targeted Therapy

  • Drugs designed against specific molecular targets (e.g., tyrosine kinase inhibitors, monoclonal antibodies)
  • More selective than traditional chemotherapy

E. Immunotherapy

  • Checkpoint inhibitors (anti-PD-1, anti-CTLA-4)
  • CAR-T cell therapy
  • Restores immune system's ability to recognize and kill cancer cells

F. Hormonal Therapy

  • Used for hormone-sensitive cancers (breast, prostate)
  • Blocks hormone production or receptor action

G. Stem Cell / Bone Marrow Transplant

  • Used in hematological malignancies after high-dose chemotherapy

3. CLASSIFICATION OF ANTICANCER DRUGS

(Based on Katzung's Basic and Clinical Pharmacology, 16th Edition)
Anticancer drugs are broadly classified into:

CLASS I: ALKYLATING AGENTS

Mechanism: Form covalent bonds with DNA, cross-link DNA strands, preventing replication. Cell cycle NON-specific.
SubclassExamples
Nitrogen mustardsCyclophosphamide, Chlorambucil, Melphalan, Ifosfamide
NitrosoureasCarmustine (BCNU), Lomustine (CCNU) - cross blood-brain barrier
Alkyl sulfonatesBusulfan
TriazinesDacarbazine, Temozolomide
Platinum analogsCisplatin, Carboplatin, Oxaliplatin
Toxicities: Myelosuppression, alopecia, nausea/vomiting, hemorrhagic cystitis (cyclophosphamide), nephrotoxicity (cisplatin)

CLASS II: ANTIMETABOLITES

Mechanism: Structural analogs of normal metabolites that interfere with nucleic acid synthesis. Cell cycle SPECIFIC (S phase).
SubclassExamplesTarget
Folate antagonistsMethotrexate, PemetrexedInhibits DHFR (dihydrofolate reductase)
Pyrimidine antagonists5-Fluorouracil (5-FU), Capecitabine, Cytarabine, GemcitabineInhibits thymidylate synthase / DNA synthesis
Purine antagonists6-Mercaptopurine, 6-Thioguanine, Fludarabine, CladribineInhibits purine synthesis
Cladribine is a purine nucleoside analog highly specific for lymphoid cells; indicated for hairy cell leukemia. It is phosphorylated to its triphosphate form which inhibits DNA polymerase-alpha and -beta.
Toxicities: Myelosuppression, mucositis, hepatotoxicity (MTX), peripheral neuropathy

CLASS III: NATURAL PRODUCT DRUGS

A. Vinca Alkaloids

Mechanism: Inhibit tubulin polymerization → disrupt microtubule/mitotic spindle assembly → mitotic arrest in metaphase → cell death. Active in M phase.
  • Vinblastine - derived from Vinca rosea; used in Hodgkin/non-Hodgkin lymphoma, breast cancer, germ cell cancer
  • Vincristine - used in ALL, lymphomas
  • Vinorelbine - used in NSCLC, breast cancer
Toxicities: Neurotoxicity (vincristine), myelosuppression (vinblastine), vesicant effect

B. Taxanes

Mechanism: Stabilize polymerized microtubules (opposite of vinca alkaloids) → prevent depolymerization → mitotic arrest.
  • Paclitaxel - ovarian, breast, lung, Kaposi's sarcoma
  • Docetaxel - breast, NSCLC, prostate
Toxicities: Peripheral neuropathy, myelosuppression, hypersensitivity

C. Topoisomerase Inhibitors

Type I Inhibitors (Camptothecins):
  • Irinotecan (prodrug → SN-38) - colorectal cancer (FOLFIRI regimen)
  • Topotecan - ovarian cancer, small cell lung cancer
Type II Inhibitors (Epipodophyllotoxins):
  • Etoposide - lung cancer, testicular cancer, lymphomas
  • Teniposide
Toxicities: Diarrhea (irinotecan - early cholinergic type + late type), myelosuppression

D. Antitumor Antibiotics

Derived from Streptomyces species. Act by binding/intercalating DNA, blocking RNA/DNA synthesis, causing strand breaks.
Anthracyclines:
  • Doxorubicin - breast, bladder, lymphoma, sarcoma
  • Daunorubicin - AML, ALL
  • Idarubicin, Epirubicin, Mitoxantrone
  • Mechanism: (1) Topo II inhibition; (2) free radical generation; (3) DNA intercalation; (4) membrane disruption
  • Key toxicity: Cardiotoxicity (dose-dependent, via free radical mechanism)
Others:
  • Bleomycin - Hodgkin lymphoma, germ cell cancer; causes pulmonary fibrosis
  • Mitomycin C - alkylating-like, cross-links DNA

CLASS IV: HORMONAL AGENTS

Mechanism: Inhibit hormone-dependent tumor growth.
DrugMechanismUse
TamoxifenEstrogen receptor antagonistBreast cancer (ER+)
FulvestrantER degraderBreast cancer
Aromatase inhibitors (Letrozole, Anastrozole)Block estrogen synthesisPostmenopausal breast cancer
Leuprolide (GnRH agonist)Reduces LH/FSH → androgen suppressionProstate cancer
Flutamide, EnzalutamideAndrogen receptor blockersProstate cancer
Corticosteroids (Prednisone)LympholyticLymphoma, leukemia

CLASS V: TARGETED / BIOLOGICAL AGENTS

A. Monoclonal Antibodies

DrugTargetUse
TrastuzumabHER2Breast cancer (HER2+)
RituximabCD20B-cell lymphoma, CLL
CetuximabEGFRColorectal, head/neck cancer
BevacizumabVEGF-ACRC, NSCLC, GBM, ovarian cancer
RamucirumabVEGF-R2Gastric, NSCLC, CRC, HCC

B. Tyrosine Kinase Inhibitors (TKIs)

DrugTargetUse
ImatinibBCR-ABL, c-kit, PDGFRCML, GIST
Erlotinib, GefitinibEGFRNSCLC
SorafenibVEGFR2/3, PDGFR-β, RafRenal cell cancer, HCC
SunitinibVEGFR, PDGFR, c-kitRenal cell cancer, GIST
PazopanibVEGFR, PDGFRRenal cell cancer

C. Antibody-Drug Conjugates (ADCs)

  • Trastuzumab-deruxtecan - HER2-expressing tumors; deruxtecan is a topo I inhibitor 10x more potent than SN-38

CLASS VI: IMMUNOTHERAPY

TypeExamplesMechanism
PD-1 inhibitorsPembrolizumab, NivolumabBlock PD-1/PD-L1 interaction, restore T-cell activity
CTLA-4 inhibitorsIpilimumabRemoves inhibitory signal on T cells
CAR-T therapyTisagenlecleucelEngineered T cells targeting CD19
InterleukinsIL-2 (Aldesleukin)Stimulates T-cell/NK cell proliferation

CLASS VII: MISCELLANEOUS

DrugMechanismUse
HydroxyureaInhibits ribonucleotide reductase (S phase)CML, sickle cell disease
L-AsparaginaseDepletes asparagineALL
ProcarbazineAlkylating/MAOI activityHodgkin lymphoma (MOPP)
Thalidomide/LenalidomideAntiangiogenic, immunomodulatoryMultiple myeloma

Summary Table: Cell Cycle Specificity

Drug ClassCell Cycle Phase
Alkylating agentsCell cycle NON-specific
AntimetabolitesS phase specific
Vinca alkaloidsM phase specific
TaxanesM phase specific
BleomycinG2/M phase
Topoisomerase inhibitorsS phase / G2
AnthracyclinesCell cycle NON-specific

Sources: Katzung's Basic and Clinical Pharmacology, 16th Edition (pp. 1495-1624); Mulholland & Greenfield's Surgery, 7th Edition (p. 232); Lippincott Illustrated Reviews: Pharmacology

1

Asking for Preferences

Presentation

Reading File
Reading File
Reading File
Running Command

mkdir -p /home/daytona/workspace/cancer-presentation

Writing File

~/cancer-presentation/cancer_pptx.js

const pptxgen = require("pptxgenjs");

const pres = new pptxgen();
pres.layout = "LAYOUT_16x9";
pres.title = "Cancer - Definition, Treatment & Anticancer Drug Classification";
pres.author = "Orris Medical Education";

// ─── THEME ───────────────────────────────────────────────────────────────────
const C = {
  navy:    "0D1B3E",   // dominant dark
  teal:    "0A7E8C",   // supporting accent
  gold:    "F4C544",   // sharp accent
  white:   "FFFFFF",
  light:   "EFF4F9",
  mid:     "C9DDE8",
  gray:    "5A6478",
  red:     "C0392B",
  green:   "1A7A4A",
  purple:  "5B3A8E",
  orange:  "D4620A",
  steel:   "2E6EA6",
};

// ─── HELPER ──────────────────────────────────────────────────────────────────
function slideHeader(slide, title, subtitle) {
  // navy bar across top
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 0.8,
    fill: { color: C.navy }, line: { color: C.navy }
  });
  // gold accent strip
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0.8, w: 10, h: 0.07,
    fill: { color: C.gold }, line: { color: C.gold }
  });
  slide.addText(title, {
    x: 0.15, y: 0, w: 9.7, h: 0.8, margin: 0,
    fontSize: 22, bold: true, color: C.white,
    fontFace: "Calibri", valign: "middle"
  });
  if (subtitle) {
    slide.addText(subtitle, {
      x: 0.15, y: 0.82, w: 9.7, h: 0.3,
      fontSize: 12, color: C.teal, fontFace: "Calibri", italic: true
    });
  }
  // light background
  slide.background = { color: C.light };
}

function footerBar(slide, src) {
  slide.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 5.35, w: 10, h: 0.275,
    fill: { color: C.navy }, line: { color: C.navy }
  });
  slide.addText(src || "Source: Katzung's Basic & Clinical Pharmacology 16e | Goldman-Cecil Medicine", {
    x: 0.2, y: 5.35, w: 9.6, h: 0.275, margin: 0,
    fontSize: 8, color: C.mid, fontFace: "Calibri", valign: "middle"
  });
}

function iconBox(slide, x, y, w, h, fillColor, icon, label, sub) {
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x, y, w, h,
    fill: { color: fillColor },
    line: { color: fillColor },
    rectRadius: 0.12,
    shadow: { type: "outer", color: "000000", blur: 5, offset: 2, angle: 135, opacity: 0.12 }
  });
  slide.addText(icon, {
    x, y: y + 0.08, w, h: 0.5, margin: 0,
    fontSize: 22, align: "center", color: C.white, fontFace: "Segoe UI Emoji"
  });
  slide.addText(label, {
    x, y: y + 0.55, w, h: 0.32, margin: 0,
    fontSize: 11, bold: true, align: "center", color: C.white, fontFace: "Calibri"
  });
  if (sub) {
    slide.addText(sub, {
      x: x + 0.05, y: y + 0.85, w: w - 0.1, h: h - 0.9, margin: 0,
      fontSize: 8.5, align: "center", color: C.white, fontFace: "Calibri",
      wrap: true
    });
  }
}

// ─── SLIDE 1 — TITLE ─────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  s.background = { color: C.navy };

  // Large cell-like decorative circle
  s.addShape(pres.shapes.OVAL, {
    x: 6.8, y: -0.6, w: 4.5, h: 4.5,
    fill: { color: "1A2E5A" }, line: { color: "1A2E5A" }
  });
  s.addShape(pres.shapes.OVAL, {
    x: 7.4, y: -0.2, w: 3.2, h: 3.2,
    fill: { color: "243770" }, line: { color: "243770" }
  });
  s.addShape(pres.shapes.OVAL, {
    x: -1, y: 3.5, w: 2.5, h: 2.5,
    fill: { color: "1A2E5A" }, line: { color: "1A2E5A" }
  });

  // Gold accent line
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0.5, y: 1.55, w: 1.5, h: 0.06,
    fill: { color: C.gold }, line: { color: C.gold }
  });

  s.addText("CANCER", {
    x: 0.5, y: 0.6, w: 8, h: 0.9,
    fontSize: 54, bold: true, color: C.white, fontFace: "Calibri",
    charSpacing: 8
  });
  s.addText("Definition  |  Treatment  |  Anticancer Drug Classification", {
    x: 0.5, y: 1.65, w: 8.5, h: 0.5,
    fontSize: 17, color: C.mid, fontFace: "Calibri", italic: true
  });

  // Tag boxes
  const tags = ["Pharmacology", "Oncology", "Clinical Medicine"];
  tags.forEach((t, i) => {
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: 0.5 + i * 2.3, y: 2.4, w: 2.1, h: 0.38,
      fill: { color: C.teal }, line: { color: C.teal }, rectRadius: 0.19
    });
    s.addText(t, {
      x: 0.5 + i * 2.3, y: 2.4, w: 2.1, h: 0.38, margin: 0,
      fontSize: 10, bold: true, color: C.white, fontFace: "Calibri",
      align: "center", valign: "middle"
    });
  });

  s.addText("Based on Katzung's Pharmacology 16e  |  Goldman-Cecil Medicine", {
    x: 0.5, y: 5.1, w: 9, h: 0.3,
    fontSize: 9, color: C.gray, fontFace: "Calibri", italic: true
  });
}

// ─── SLIDE 2 — AGENDA ────────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Agenda");
  footerBar(s);

  const items = [
    { n: "01", title: "Definition of Cancer", sub: "What is cancer? Key hallmarks & types" },
    { n: "02", title: "Cancer vs Normal Cell", sub: "Benign vs malignant comparison" },
    { n: "03", title: "Treatment Modalities", sub: "Surgery, Radiation, Chemo, Immunotherapy & more" },
    { n: "04", title: "Classification of Anticancer Drugs", sub: "7 major classes with mechanisms & examples" },
    { n: "05", title: "Cell Cycle Specificity", sub: "Which drugs act at which phase" },
  ];

  items.forEach((item, i) => {
    const row = Math.floor(i / 3);
    const col = i % 3;
    const x = 0.3 + col * 3.2;
    const y = 1.2 + row * 2.0;
    const colors = [C.navy, C.teal, C.steel, C.purple, C.green];

    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y, w: 3.0, h: 1.7,
      fill: { color: colors[i] }, line: { color: colors[i] },
      rectRadius: 0.1,
      shadow: { type: "outer", color: "000000", blur: 6, offset: 2, angle: 135, opacity: 0.15 }
    });
    s.addText(item.n, {
      x, y: y + 0.1, w: 3.0, h: 0.45, margin: 0,
      fontSize: 28, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
    });
    s.addText(item.title, {
      x: x + 0.1, y: y + 0.58, w: 2.8, h: 0.4, margin: 0,
      fontSize: 12, bold: true, color: C.white, fontFace: "Calibri", align: "center"
    });
    s.addText(item.sub, {
      x: x + 0.1, y: y + 1.0, w: 2.8, h: 0.55, margin: 0,
      fontSize: 9, color: C.mid, fontFace: "Calibri", align: "center", wrap: true
    });
  });
}

// ─── SLIDE 3 — DEFINITION ────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "What is Cancer?", "Definition & Core Concepts");
  footerBar(s);

  // Big quote box
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.3, y: 1.1, w: 9.4, h: 1.0,
    fill: { color: C.navy }, line: { color: C.navy }, rectRadius: 0.1
  });
  s.addText([
    { text: "Cancer", options: { bold: true, color: C.gold } },
    { text: " is a group of diseases characterized by ", options: { color: C.white } },
    { text: "uncontrolled, autonomous proliferation", options: { bold: true, color: C.teal } },
    { text: " of cells that have escaped normal regulatory mechanisms of growth and division.", options: { color: C.white } }
  ], {
    x: 0.4, y: 1.1, w: 9.2, h: 1.0, margin: 8,
    fontSize: 13, fontFace: "Calibri", valign: "middle"
  });

  // 6 hallmarks
  const hallmarks = [
    { icon: "🔁", label: "Self-sufficient\nGrowth Signals" },
    { icon: "🚫", label: "Evades\nGrowth Inhibitors" },
    { icon: "💀", label: "Resists\nApoptosis" },
    { icon: "♾️", label: "Limitless\nReplication" },
    { icon: "🩸", label: "Sustained\nAngiogenesis" },
    { icon: "🌐", label: "Invasion &\nMetastasis" },
  ];

  hallmarks.forEach((h, i) => {
    const x = 0.3 + i * 1.57;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y: 2.25, w: 1.45, h: 1.5,
      fill: { color: i % 2 === 0 ? C.teal : C.steel },
      line: { color: i % 2 === 0 ? C.teal : C.steel },
      rectRadius: 0.1
    });
    s.addText(h.icon, {
      x, y: 2.28, w: 1.45, h: 0.5, margin: 0,
      fontSize: 20, align: "center", fontFace: "Segoe UI Emoji"
    });
    s.addText(h.label, {
      x, y: 2.78, w: 1.45, h: 0.9, margin: 0,
      fontSize: 9, bold: true, color: C.white, fontFace: "Calibri",
      align: "center", wrap: true
    });
  });

  s.addText("Hallmarks of Cancer (Hanahan & Weinberg)", {
    x: 0.3, y: 3.82, w: 9.4, h: 0.25,
    fontSize: 9, italic: true, color: C.gray, fontFace: "Calibri", align: "center"
  });

  // Types row
  s.addText("Major Types by Tissue Origin:", {
    x: 0.3, y: 4.12, w: 9.4, h: 0.3,
    fontSize: 11, bold: true, color: C.navy, fontFace: "Calibri"
  });
  const types = [
    ["Carcinoma", "Epithelial cells", C.navy],
    ["Sarcoma", "Connective tissue", C.steel],
    ["Leukemia", "Blood-forming cells", C.teal],
    ["Lymphoma", "Lymphoid tissue", C.purple],
    ["Myeloma", "Plasma cells", C.green],
  ];
  types.forEach(([name, org, clr], i) => {
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: 0.28 + i * 1.89, y: 4.44, w: 1.78, h: 0.65,
      fill: { color: clr }, line: { color: clr }, rectRadius: 0.08
    });
    s.addText([
      { text: name + "\n", options: { bold: true, fontSize: 10, color: C.white } },
      { text: org, options: { fontSize: 8, color: C.mid } }
    ], {
      x: 0.28 + i * 1.89, y: 4.44, w: 1.78, h: 0.65, margin: 4,
      fontFace: "Calibri", align: "center", valign: "middle"
    });
  });
}

// ─── SLIDE 4 — BENIGN vs MALIGNANT ───────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Benign vs Malignant Tumors", "Key Distinguishing Features");
  footerBar(s);

  // Header row
  const colW = 3.8;
  [C.navy, C.teal, C.red].forEach((c, i) => {
    s.addShape(pres.shapes.RECTANGLE, {
      x: 0.15 + i * colW, y: 1.05, w: colW - 0.05, h: 0.42,
      fill: { color: c }, line: { color: c }
    });
  });
  ["Feature", "Benign Tumor", "Malignant Tumor (Cancer)"].forEach((h, i) => {
    s.addText(h, {
      x: 0.15 + i * colW, y: 1.05, w: colW - 0.05, h: 0.42, margin: 0,
      fontSize: 12, bold: true, color: C.white, fontFace: "Calibri",
      align: "center", valign: "middle"
    });
  });

  const rows = [
    ["Growth Rate", "Slow", "Rapid & uncontrolled"],
    ["Local Invasion", "❌ No", "✅ Yes"],
    ["Metastasis", "❌ No", "✅ Yes"],
    ["Differentiation", "Well-differentiated", "Poorly differentiated"],
    ["Capsule", "Usually present", "Absent"],
    ["Recurrence", "Rare after removal", "Common"],
    ["Threat to life", "Usually not", "Often fatal if untreated"],
  ];

  rows.forEach((row, ri) => {
    const bg = ri % 2 === 0 ? "EFF4F9" : C.white;
    row.forEach((cell, ci) => {
      s.addShape(pres.shapes.RECTANGLE, {
        x: 0.15 + ci * colW, y: 1.47 + ri * 0.48, w: colW - 0.05, h: 0.48,
        fill: { color: bg }, line: { color: C.mid }
      });
      const isGood = cell.includes("❌");
      const isBad = cell.includes("✅");
      s.addText(cell, {
        x: 0.15 + ci * colW, y: 1.47 + ri * 0.48, w: colW - 0.05, h: 0.48, margin: 4,
        fontSize: ci === 0 ? 11 : 10.5,
        bold: ci === 0,
        color: ci === 0 ? C.navy : (isBad ? C.red : (isGood ? C.green : C.gray)),
        fontFace: "Calibri", valign: "middle", align: ci === 0 ? "left" : "center"
      });
    });
  });
}

// ─── SLIDE 5 — TREATMENT ─────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Treatment of Cancer", "Modalities & Goals");
  footerBar(s);

  const modalities = [
    { icon: "🔪", label: "Surgery", color: C.navy,
      desc: "Remove solid tumors\nCurative for early-stage\nDebulking for advanced" },
    { icon: "☢️", label: "Radiation\nTherapy", color: C.steel,
      desc: "Ionizing radiation\nDamages tumor DNA\nExternal or brachytherapy" },
    { icon: "💊", label: "Chemo-\ntherapy", color: C.teal,
      desc: "Systemic cytotoxic drugs\nTargets rapidly dividing cells\nAdjuvant or neoadjuvant" },
    { icon: "🎯", label: "Targeted\nTherapy", color: C.purple,
      desc: "TKIs, monoclonal Abs\nHits specific molecular targets\nFewer side effects" },
    { icon: "🛡️", label: "Immuno-\ntherapy", color: C.green,
      desc: "PD-1/CTLA-4 inhibitors\nCAR-T cell therapy\nRestores immune attack" },
    { icon: "⚗️", label: "Hormonal\nTherapy", color: C.orange,
      desc: "Blocks hormone receptors\nBreast & prostate cancer\nTamoxifen, Leuprolide" },
  ];

  modalities.forEach((m, i) => {
    const col = i % 3;
    const row = Math.floor(i / 3);
    const x = 0.22 + col * 3.2;
    const y = 1.1 + row * 2.1;

    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y, w: 3.0, h: 1.95,
      fill: { color: m.color }, line: { color: m.color }, rectRadius: 0.12,
      shadow: { type: "outer", color: "000000", blur: 8, offset: 3, angle: 135, opacity: 0.15 }
    });
    s.addText(m.icon, {
      x, y: y + 0.05, w: 3.0, h: 0.5, margin: 0,
      fontSize: 24, align: "center", fontFace: "Segoe UI Emoji"
    });
    s.addText(m.label, {
      x, y: y + 0.52, w: 3.0, h: 0.48, margin: 0,
      fontSize: 12, bold: true, color: C.white, fontFace: "Calibri", align: "center"
    });
    s.addText(m.desc, {
      x: x + 0.1, y: y + 0.98, w: 2.8, h: 0.9, margin: 0,
      fontSize: 9, color: C.mid, fontFace: "Calibri", align: "center", wrap: true
    });
  });
}

// ─── SLIDE 6 — ANTICANCER DRUG OVERVIEW ──────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Classification of Anticancer Drugs", "Overview — 7 Major Classes");
  footerBar(s);

  const classes = [
    { num: "I",   label: "Alkylating Agents",       color: C.navy,   icon: "🧪", phase: "Non-specific" },
    { num: "II",  label: "Antimetabolites",          color: C.teal,   icon: "🔬", phase: "S phase" },
    { num: "III", label: "Natural Products",         color: C.steel,  icon: "🌿", phase: "M / S / G2" },
    { num: "IV",  label: "Hormonal Agents",          color: C.purple, icon: "⚗️", phase: "Non-specific" },
    { num: "V",   label: "Targeted / Biologicals",   color: C.green,  icon: "🎯", phase: "Non-specific" },
    { num: "VI",  label: "Immunotherapy",            color: C.orange, icon: "🛡️", phase: "Non-specific" },
    { num: "VII", label: "Miscellaneous",             color: C.gray,   icon: "💡", phase: "Varies" },
  ];

  classes.forEach((c, i) => {
    const x = 0.22 + (i % 4) * 2.4;
    const y = 1.1 + Math.floor(i / 4) * 2.1;

    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y, w: 2.25, h: 1.85,
      fill: { color: c.color }, line: { color: c.color }, rectRadius: 0.12,
      shadow: { type: "outer", color: "000000", blur: 5, offset: 2, angle: 135, opacity: 0.12 }
    });
    s.addText(`Class ${c.num}`, {
      x, y: y + 0.08, w: 2.25, h: 0.32, margin: 0,
      fontSize: 10, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
    });
    s.addText(c.icon, {
      x, y: y + 0.36, w: 2.25, h: 0.42, margin: 0,
      fontSize: 20, align: "center", fontFace: "Segoe UI Emoji"
    });
    s.addText(c.label, {
      x: x + 0.05, y: y + 0.78, w: 2.15, h: 0.55, margin: 0,
      fontSize: 10, bold: true, color: C.white, fontFace: "Calibri", align: "center", wrap: true
    });
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: x + 0.2, y: y + 1.42, w: 1.85, h: 0.3,
      fill: { color: "00000030" }, line: { color: "00000000" }, rectRadius: 0.15
    });
    s.addText(c.phase, {
      x: x + 0.2, y: y + 1.42, w: 1.85, h: 0.3, margin: 0,
      fontSize: 8.5, color: C.white, fontFace: "Calibri", align: "center", valign: "middle"
    });
  });
}

// ─── SLIDE 7 — CLASS I ALKYLATING ────────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class I — Alkylating Agents", "Cell Cycle Non-Specific");
  footerBar(s);

  // Mechanism box
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.3, y: 1.0, w: 9.4, h: 0.72,
    fill: { color: C.navy }, line: { color: C.navy }, rectRadius: 0.1
  });
  s.addText([
    { text: "⚙️ Mechanism: ", options: { bold: true, color: C.gold } },
    { text: "Form covalent bonds with DNA, cross-link DNA strands, prevent replication. ", options: { color: C.white } },
    { text: "Cell cycle NON-specific.", options: { bold: true, color: C.teal } }
  ], {
    x: 0.4, y: 1.0, w: 9.2, h: 0.72, margin: 6,
    fontSize: 12, fontFace: "Calibri", valign: "middle"
  });

  const subclasses = [
    { name: "Nitrogen Mustards", examples: "Cyclophosphamide\nChlorambucil\nMelphalan\nIfosfamide", color: C.navy },
    { name: "Nitrosoureas", examples: "Carmustine (BCNU)\nLomustine (CCNU)\n(Cross BBB ✓)", color: C.steel },
    { name: "Alkyl Sulfonates", examples: "Busulfan", color: C.teal },
    { name: "Triazines", examples: "Dacarbazine\nTemozolomide", color: C.purple },
    { name: "Platinum Analogs", examples: "Cisplatin\nCarboplatin\nOxaliplatin", color: C.green },
  ];

  subclasses.forEach((sc, i) => {
    const x = 0.25 + (i % 3) * 3.18;
    const y = 1.88 + Math.floor(i / 3) * 1.65;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y, w: 3.0, h: 1.55,
      fill: { color: sc.color }, line: { color: sc.color }, rectRadius: 0.1
    });
    s.addText(sc.name, {
      x, y: y + 0.07, w: 3.0, h: 0.35, margin: 0,
      fontSize: 11, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
    });
    s.addText(sc.examples, {
      x: x + 0.1, y: y + 0.44, w: 2.8, h: 1.0, margin: 0,
      fontSize: 9.5, color: C.white, fontFace: "Calibri", align: "center", wrap: true
    });
  });

  s.addText("⚠️ Key Toxicities: Myelosuppression • Alopecia • Nausea/Vomiting • Hemorrhagic cystitis (Cyclophosphamide) • Nephrotoxicity (Cisplatin)", {
    x: 0.3, y: 5.05, w: 9.4, h: 0.28,
    fontSize: 8.5, color: C.red, fontFace: "Calibri", bold: true
  });
}

// ─── SLIDE 8 — CLASS II ANTIMETABOLITES ──────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class II — Antimetabolites", "S Phase Specific");
  footerBar(s);

  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.3, y: 1.0, w: 9.4, h: 0.72,
    fill: { color: C.teal }, line: { color: C.teal }, rectRadius: 0.1
  });
  s.addText([
    { text: "⚙️ Mechanism: ", options: { bold: true, color: C.gold } },
    { text: "Structural analogs of normal metabolites that interfere with nucleic acid synthesis. ", options: { color: C.white } },
    { text: "S phase specific.", options: { bold: true, color: C.navy } }
  ], {
    x: 0.4, y: 1.0, w: 9.2, h: 0.72, margin: 6,
    fontSize: 12, fontFace: "Calibri", valign: "middle"
  });

  const groups = [
    {
      name: "Folate Antagonists", color: C.navy,
      items: ["Methotrexate — inhibits DHFR", "Pemetrexed — multi-enzyme inhibitor"],
      use: "ALL, Choriocarcinoma, NSCLC, RA"
    },
    {
      name: "Pyrimidine Antagonists", color: C.steel,
      items: ["5-Fluorouracil (5-FU) — inhibits thymidylate synthase", "Capecitabine — oral prodrug of 5-FU", "Cytarabine (Ara-C) — AML", "Gemcitabine — pancreatic, lung, breast"],
      use: "Colon, breast, pancreatic cancers"
    },
    {
      name: "Purine Antagonists", color: C.purple,
      items: ["6-Mercaptopurine — ALL", "6-Thioguanine — AML", "Fludarabine — CLL", "Cladribine — Hairy cell leukemia"],
      use: "Leukemias, Lymphomas"
    },
  ];

  groups.forEach((g, i) => {
    const x = 0.25 + i * 3.18;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y: 1.88, w: 3.05, h: 3.2,
      fill: { color: g.color }, line: { color: g.color }, rectRadius: 0.1
    });
    s.addText(g.name, {
      x, y: 1.95, w: 3.05, h: 0.38, margin: 0,
      fontSize: 11, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
    });
    g.items.forEach((item, j) => {
      s.addText("▸ " + item, {
        x: x + 0.15, y: 2.38 + j * 0.52, w: 2.75, h: 0.48, margin: 0,
        fontSize: 9, color: C.white, fontFace: "Calibri", wrap: true
      });
    });
    s.addShape(pres.shapes.RECTANGLE, {
      x, y: 4.72, w: 3.05, h: 0.02,
      fill: { color: C.gold }, line: { color: C.gold }
    });
    s.addText("Use: " + g.use, {
      x: x + 0.1, y: 4.76, w: 2.85, h: 0.25,
      fontSize: 8, color: C.mid, fontFace: "Calibri", italic: true
    });
  });
}

// ─── SLIDE 9 — CLASS III NATURAL PRODUCTS ────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class III — Natural Product Drugs", "Vinca Alkaloids | Taxanes | Topo Inhibitors | Antitumor Antibiotics");
  footerBar(s);

  const groups = [
    {
      name: "Vinca Alkaloids\n(M phase)", color: C.navy, x: 0.2, y: 1.1,
      items: ["Vinblastine — Hodgkin lymphoma, breast", "Vincristine — ALL, lymphoma", "Vinorelbine — NSCLC"],
      mech: "↓ Tubulin polymerization → mitotic arrest in metaphase"
    },
    {
      name: "Taxanes\n(M phase)", color: C.teal, x: 5.1, y: 1.1,
      items: ["Paclitaxel — ovarian, breast, lung", "Docetaxel — breast, NSCLC, prostate"],
      mech: "Stabilize microtubules → prevent depolymerization"
    },
    {
      name: "Topo I Inhibitors\n(Camptothecins)", color: C.steel, x: 0.2, y: 3.1,
      items: ["Irinotecan — CRC (FOLFIRI regimen)", "Topotecan — ovarian, SCLC"],
      mech: "Irinotecan prodrug → SN-38 (1000× more potent)"
    },
    {
      name: "Antitumor Antibiotics\n(Streptomyces)", color: C.purple, x: 5.1, y: 3.1,
      items: ["Doxorubicin — breast, lymphoma, sarcoma", "Bleomycin — Hodgkin, germ cell → pulm. fibrosis", "Mitomycin C — GI cancers"],
      mech: "DNA intercalation, Topo II inhibition, free radicals"
    },
  ];

  groups.forEach(g => {
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: g.x, y: g.y, w: 4.7, h: 1.85,
      fill: { color: g.color }, line: { color: g.color }, rectRadius: 0.1,
      shadow: { type: "outer", color: "000000", blur: 5, offset: 2, angle: 135, opacity: 0.12 }
    });
    s.addText(g.name, {
      x: g.x + 0.1, y: g.y + 0.05, w: 4.5, h: 0.5, margin: 0,
      fontSize: 11, bold: true, color: C.gold, fontFace: "Calibri"
    });
    s.addText("⚙️ " + g.mech, {
      x: g.x + 0.1, y: g.y + 0.55, w: 4.5, h: 0.35, margin: 0,
      fontSize: 8.5, color: C.mid, fontFace: "Calibri", italic: true, wrap: true
    });
    g.items.forEach((item, j) => {
      s.addText("▸ " + item, {
        x: g.x + 0.15, y: g.y + 0.92 + j * 0.28, w: 4.4, h: 0.28, margin: 0,
        fontSize: 9, color: C.white, fontFace: "Calibri"
      });
    });
  });
}

// ─── SLIDE 10 — CLASS IV HORMONAL ────────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class IV — Hormonal Agents", "Hormone-sensitive Cancers: Breast & Prostate");
  footerBar(s);

  const table = [
    ["Drug / Class", "Mechanism", "Key Use"],
    ["Tamoxifen", "ER antagonist (SERM)", "Breast cancer (ER+)"],
    ["Fulvestrant", "ER degrader", "ER+ breast cancer"],
    ["Letrozole / Anastrozole", "Aromatase inhibitor → ↓ estrogen", "Postmenopausal breast cancer"],
    ["Leuprolide", "GnRH agonist → ↓ LH/FSH → ↓ androgens", "Prostate cancer"],
    ["Flutamide / Enzalutamide", "Androgen receptor blocker", "Prostate cancer"],
    ["Prednisone / Dexamethasone", "Lympholytic corticosteroid", "Lymphoma, leukemia, myeloma"],
  ];

  const colWidths = [2.8, 4.0, 2.8];
  const rowHeight = 0.52;
  const startY = 1.1;
  const startX = 0.22;

  table.forEach((row, ri) => {
    row.forEach((cell, ci) => {
      const x = startX + colWidths.slice(0, ci).reduce((a, b) => a + b, 0) + ci * 0.05;
      const y = startY + ri * rowHeight;
      const isHeader = ri === 0;
      s.addShape(pres.shapes.RECTANGLE, {
        x, y, w: colWidths[ci], h: rowHeight,
        fill: { color: isHeader ? C.navy : (ri % 2 === 0 ? "EFF4F9" : C.white) },
        line: { color: C.mid }
      });
      s.addText(cell, {
        x, y, w: colWidths[ci], h: rowHeight, margin: 5,
        fontSize: isHeader ? 11 : 10,
        bold: isHeader || ci === 0,
        color: isHeader ? C.white : (ci === 0 ? C.navy : C.gray),
        fontFace: "Calibri", valign: "middle",
        align: isHeader ? "center" : "left", wrap: true
      });
    });
  });

  s.addText("💡 Hormonal therapy blocks hormone-dependent signaling that drives tumor growth in breast and prostate cancers.", {
    x: 0.22, y: 4.9, w: 9.5, h: 0.4,
    fontSize: 10, color: C.navy, fontFace: "Calibri",
    fill: { color: "E8F4FD" }, italic: true
  });
}

// ─── SLIDE 11 — CLASS V TARGETED ─────────────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class V — Targeted & Biological Agents", "Monoclonal Antibodies | TKIs | ADCs");
  footerBar(s);

  // Monoclonal Abs
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.2, y: 1.05, w: 4.75, h: 2.0,
    fill: { color: C.navy }, line: { color: C.navy }, rectRadius: 0.1
  });
  s.addText("🔬 Monoclonal Antibodies", {
    x: 0.3, y: 1.08, w: 4.5, h: 0.38, margin: 0,
    fontSize: 12, bold: true, color: C.gold, fontFace: "Calibri"
  });
  [
    "Trastuzumab — HER2 | Breast cancer",
    "Rituximab — CD20 | B-cell lymphoma",
    "Cetuximab — EGFR | CRC, head/neck",
    "Bevacizumab — VEGF-A | CRC, NSCLC, GBM",
    "Ramucirumab — VEGFR2 | Gastric, NSCLC",
  ].forEach((item, i) => {
    s.addText("▸ " + item, {
      x: 0.35, y: 1.5 + i * 0.3, w: 4.5, h: 0.3, margin: 0,
      fontSize: 9.5, color: C.white, fontFace: "Calibri"
    });
  });

  // TKIs
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 5.1, y: 1.05, w: 4.75, h: 2.0,
    fill: { color: C.steel }, line: { color: C.steel }, rectRadius: 0.1
  });
  s.addText("🎯 Tyrosine Kinase Inhibitors (TKIs)", {
    x: 5.2, y: 1.08, w: 4.5, h: 0.38, margin: 0,
    fontSize: 12, bold: true, color: C.gold, fontFace: "Calibri"
  });
  [
    "Imatinib — BCR-ABL, c-kit | CML, GIST",
    "Erlotinib / Gefitinib — EGFR | NSCLC",
    "Sorafenib — VEGFR2/3, Raf | RCC, HCC",
    "Sunitinib — VEGFR, PDGFR | RCC, GIST",
    "Pazopanib — VEGFR, PDGFR | RCC",
  ].forEach((item, i) => {
    s.addText("▸ " + item, {
      x: 5.2, y: 1.5 + i * 0.3, w: 4.5, h: 0.3, margin: 0,
      fontSize: 9.5, color: C.white, fontFace: "Calibri"
    });
  });

  // ADC + VEGF note
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.2, y: 3.18, w: 9.65, h: 0.92,
    fill: { color: C.purple }, line: { color: C.purple }, rectRadius: 0.1
  });
  s.addText("💉 Antibody-Drug Conjugate (ADC):", {
    x: 0.3, y: 3.22, w: 4.5, h: 0.35, margin: 0,
    fontSize: 11, bold: true, color: C.gold, fontFace: "Calibri"
  });
  s.addText("Trastuzumab-Deruxtecan — HER2-expressing tumors | Deruxtecan: Topo I inhibitor 10× more potent than SN-38 (Katzung 16e)", {
    x: 0.3, y: 3.6, w: 9.3, h: 0.42, margin: 0,
    fontSize: 9.5, color: C.white, fontFace: "Calibri"
  });

  s.addText("⚠️ Anti-VEGF agents (Bevacizumab, Sorafenib, Sunitinib): Risk of HTN, thromboembolism, GI perforation, poor wound healing. Metabolised by CYP3A4.", {
    x: 0.2, y: 4.2, w: 9.65, h: 0.42,
    fontSize: 8.5, color: C.red, fontFace: "Calibri", bold: true
  });
}

// ─── SLIDE 12 — CLASS VI IMMUNOTHERAPY ───────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class VI — Immunotherapy", "Checkpoint Inhibitors | CAR-T | Cytokines");
  footerBar(s);

  const cards = [
    { icon: "🔓", title: "PD-1 / PD-L1\nInhibitors", color: C.navy,
      items: ["Pembrolizumab (Keytruda)", "Nivolumab (Opdivo)", "Atezolizumab (anti-PD-L1)"],
      mech: "Block PD-1/PD-L1 interaction → restore T-cell cytotoxic activity",
      use: "Melanoma, NSCLC, bladder, HNSCC" },
    { icon: "🚧", title: "CTLA-4\nInhibitors", color: C.teal,
      items: ["Ipilimumab (Yervoy)"],
      mech: "Remove CTLA-4 inhibitory brake → enhance T-cell priming",
      use: "Melanoma (± nivolumab combination)" },
    { icon: "🧬", title: "CAR-T Cell\nTherapy", color: C.purple,
      items: ["Tisagenlecleucel (anti-CD19)", "Axicabtagene ciloleucel"],
      mech: "Engineered T cells with chimeric antigen receptor targeting tumor antigens",
      use: "Relapsed/refractory ALL, B-cell lymphoma" },
    { icon: "⚡", title: "Cytokines &\nOther", color: C.steel,
      items: ["IL-2 (Aldesleukin)", "Interferon-α (IFN-α)"],
      mech: "Stimulate proliferation of T cells and NK cells",
      use: "RCC, melanoma, hairy cell leukemia" },
  ];

  cards.forEach((c, i) => {
    const x = 0.2 + (i % 2) * 4.9;
    const y = 1.08 + Math.floor(i / 2) * 2.15;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y, w: 4.65, h: 2.0,
      fill: { color: c.color }, line: { color: c.color }, rectRadius: 0.1,
      shadow: { type: "outer", color: "000000", blur: 5, offset: 2, angle: 135, opacity: 0.12 }
    });
    s.addText(c.icon + " " + c.title, {
      x: x + 0.1, y: y + 0.05, w: 4.4, h: 0.5, margin: 0,
      fontSize: 11, bold: true, color: C.gold, fontFace: "Calibri"
    });
    s.addText("⚙️ " + c.mech, {
      x: x + 0.1, y: y + 0.55, w: 4.4, h: 0.35, margin: 0,
      fontSize: 8.5, color: C.mid, fontFace: "Calibri", italic: true, wrap: true
    });
    c.items.forEach((item, j) => {
      s.addText("▸ " + item, {
        x: x + 0.15, y: y + 0.92 + j * 0.26, w: 4.3, h: 0.26, margin: 0,
        fontSize: 9, color: C.white, fontFace: "Calibri"
      });
    });
    s.addText("Use: " + c.use, {
      x: x + 0.1, y: y + 1.7, w: 4.4, h: 0.26, margin: 0,
      fontSize: 8.5, color: C.gold, fontFace: "Calibri", italic: true
    });
  });
}

// ─── SLIDE 13 — CLASS VII + CELL CYCLE ───────────────────────────────────────
{
  const s = pres.addSlide();
  slideHeader(s, "Class VII — Miscellaneous  |  Cell Cycle Specificity", "");
  footerBar(s);

  // Misc table
  const misc = [
    ["Drug", "Mechanism", "Use"],
    ["Hydroxyurea", "Inhibits ribonucleotide reductase (S phase)", "CML, sickle cell"],
    ["L-Asparaginase", "Depletes asparagine → ↓ protein synthesis", "ALL"],
    ["Procarbazine", "Alkylating + MAOI activity", "Hodgkin lymphoma (MOPP)"],
    ["Thalidomide /\nLenalidomide", "Antiangiogenic + immunomodulatory", "Multiple myeloma"],
  ];

  misc.forEach((row, ri) => {
    row.forEach((cell, ci) => {
      const colW = [2.2, 4.5, 2.7];
      const x = 0.2 + colW.slice(0, ci).reduce((a, b) => a + b, 0) + ci * 0.05;
      const y = 1.05 + ri * 0.5;
      s.addShape(pres.shapes.RECTANGLE, {
        x, y, w: colW[ci], h: 0.5,
        fill: { color: ri === 0 ? C.navy : (ri % 2 === 0 ? "EFF4F9" : C.white) },
        line: { color: C.mid }
      });
      s.addText(cell, {
        x, y, w: colW[ci], h: 0.5, margin: 4,
        fontSize: ri === 0 ? 11 : 9.5,
        bold: ri === 0 || ci === 0,
        color: ri === 0 ? C.white : (ci === 0 ? C.navy : C.gray),
        fontFace: "Calibri", valign: "middle", wrap: true
      });
    });
  });

  // Cell cycle chart
  s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.2, y: 3.6, w: 9.65, h: 1.6,
    fill: { color: C.navy }, line: { color: C.navy }, rectRadius: 0.1
  });
  s.addText("Cell Cycle Phase Specificity Summary", {
    x: 0.3, y: 3.64, w: 9.4, h: 0.35, margin: 0,
    fontSize: 12, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
  });

  const phases = [
    { phase: "S Phase", drugs: "Antimetabolites\nHydroxyurea\nCamptothecins", color: C.teal },
    { phase: "M Phase", drugs: "Vinca Alkaloids\nTaxanes", color: C.steel },
    { phase: "G2 / M", drugs: "Bleomycin\nEtoposide", color: C.purple },
    { phase: "Non-Specific", drugs: "Alkylating Agents\nAnthracyclines\nHormonal agents", color: C.green },
  ];

  phases.forEach((p, i) => {
    const x = 0.35 + i * 2.37;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y: 4.02, w: 2.2, h: 1.1,
      fill: { color: p.color }, line: { color: p.color }, rectRadius: 0.08
    });
    s.addText(p.phase, {
      x, y: 4.05, w: 2.2, h: 0.33, margin: 0,
      fontSize: 10, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
    });
    s.addText(p.drugs, {
      x, y: 4.38, w: 2.2, h: 0.72, margin: 0,
      fontSize: 8.5, color: C.white, fontFace: "Calibri", align: "center", wrap: true
    });
  });
}

// ─── SLIDE 14 — SUMMARY ──────────────────────────────────────────────────────
{
  const s = pres.addSlide();
  s.background = { color: C.navy };

  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 0, w: 10, h: 0.07,
    fill: { color: C.gold }, line: { color: C.gold }
  });
  s.addShape(pres.shapes.RECTANGLE, {
    x: 0, y: 5.555, w: 10, h: 0.07,
    fill: { color: C.gold }, line: { color: C.gold }
  });

  s.addText("Key Takeaways", {
    x: 0.5, y: 0.15, w: 9, h: 0.6,
    fontSize: 28, bold: true, color: C.gold, fontFace: "Calibri", align: "center"
  });

  const points = [
    ["🔬 Cancer", "Uncontrolled autonomous cell proliferation escaping normal growth regulation; classified as carcinoma, sarcoma, leukemia, lymphoma, myeloma."],
    ["💊 Treatment", "Surgery · Radiation · Chemotherapy · Targeted therapy · Immunotherapy · Hormonal therapy — often combined for best outcomes."],
    ["🧪 Alkylating (I)", "Cell cycle non-specific; cross-link DNA. Cisplatin, Cyclophosphamide, Temozolomide."],
    ["🔬 Antimetabolites (II)", "S-phase specific; structural analogs. MTX (DHFR inhibitor), 5-FU, Gemcitabine, Cladribine."],
    ["🌿 Natural Products (III)", "Vinca alkaloids (M phase) · Taxanes (M phase) · Topo inhibitors · Antitumor antibiotics (Doxorubicin → cardiotoxicity)."],
    ["⚗️ Hormonal (IV)", "ER antagonists, aromatase inhibitors, GnRH agonists, androgen blockers — breast & prostate cancer."],
    ["🎯 Targeted/Immuno (V-VI)", "Monoclonal Abs (Trastuzumab, Bevacizumab), TKIs (Imatinib, Sorafenib), Checkpoint inhibitors (Pembrolizumab), CAR-T."],
  ];

  points.forEach((p, i) => {
    const col = i % 2;
    const row = Math.floor(i / 2);
    const x = 0.25 + col * 5.0;
    const y = 0.88 + row * 1.1;
    s.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x, y, w: 4.75, h: 1.0,
      fill: { color: "1A2E5A" }, line: { color: C.teal }, rectRadius: 0.08
    });
    s.addText([
      { text: p[0] + "  ", options: { bold: true, color: C.gold, fontSize: 10 } },
      { text: p[1], options: { color: C.mid, fontSize: 9 } }
    ], {
      x: x + 0.12, y, w: 4.5, h: 1.0, margin: 6,
      fontFace: "Calibri", valign: "middle", wrap: true
    });
  });

  s.addText("Orris Medical Education  |  Based on Katzung's Pharmacology 16e & Goldman-Cecil Medicine", {
    x: 0.5, y: 5.3, w: 9, h: 0.25,
    fontSize: 8.5, color: C.gray, fontFace: "Calibri", align: "center"
  });
}

// ─── SAVE ─────────────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/cancer-presentation/Cancer_Anticancer_Drugs.pptx" })
  .then(() => console.log("✅ Saved: Cancer_Anticancer_Drugs.pptx"))
  .catch(e => { console.error("❌ Error:", e); process.exit(1); });
Running Command

cd /home/daytona/workspace/cancer-presentation && node cancer_pptx.js

Running Command

ls -lh /home/daytona/workspace/cancer-presentation/Cancer_Anticancer_Drugs.pptx

Your presentation is ready! 🎉

Cancer Anticancer Drugs

Presentation · PPTX


Here's what's inside the 14-slide deck (navy/teal/gold color theme, professional medical design):
SlideContent
1Title slide — bold cancer theme with decorative elements
2Agenda — 5 topic cards with numbered sections
3Definition of Cancer — hallmarks of cancer + 5 tumor types
4Benign vs Malignant — full comparison table
5Treatment Modalities — 6 cards (Surgery, RT, Chemo, Targeted, Immuno, Hormonal)
6Anticancer Drug Classification Overview — 7 class cards with cell cycle phase
7Class I — Alkylating Agents (5 subclasses + toxicities)
8Class II — Antimetabolites (Folate/Pyrimidine/Purine antagonists)
9Class III — Natural Products (Vinca, Taxanes, Topo inhibitors, Antibiotics)
10Class IV — Hormonal Agents (table with drugs, mechanism, use)
11Class V — Targeted Agents (mAbs, TKIs, ADCs)
12Class VI — Immunotherapy (PD-1, CTLA-4, CAR-T, Cytokines)
13Class VII Miscellaneous + Cell Cycle Specificity Summary chart
14Key Takeaways summary slide
This is a shared conversation. Sign in to Orris to start your own chat.